William Blair Has Negative Outlook of TRDA Q3 Earnings

Key Points

• William Blair has downgraded its earnings estimates for Entrada Therapeutics (TRDA), projecting Q3 2025 earnings per share (EPS) at ($0.88), down from a previous estimate of ($0.76).
• In its latest quarterly earnings, Entrada Therapeutics reported an EPS of ($1.04), missing the analysts' consensus estimate of ($0.86) by ($0.18).
• Several analysts have revised their ratings, with one firm lowering the stock from a "hold" to a "sell," while the overall consensus remains a "Moderate Buy" with an average price target of $25.67.

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair cut their Q3 2025 earnings per share estimates for shares of Entrada Therapeutics in a report issued on Wednesday, August 6th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.88) per share for the quarter, down from their prior estimate of ($0.76). The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. William Blair also issued estimates for Entrada Therapeutics' Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($3.13) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.88) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($3.44) EPS and FY2027 earnings at ($3.83) EPS.

TRDA has been the topic of several other research reports. Wall Street Zen lowered Entrada Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $25.67.

Entrada Therapeutics Trading Down 3.3%

Shares of NASDAQ:TRDA traded down $0.17 during trading on Monday, hitting $5.02. 242,106 shares of the stock were exchanged, compared to its average volume of 217,327. The company has a fifty day moving average price of $6.84 and a two-hundred day moving average price of $8.91. The company has a market cap of $190.96 million, a PE ratio of -2.82 and a beta of -0.12. Entrada Therapeutics has a 12-month low of $4.93 and a 12-month high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.18). The firm had revenue of $1.98 million for the quarter, compared to analysts' expectations of $8.17 million. Entrada Therapeutics had a negative return on equity of 17.81% and a negative net margin of 92.30%.

Insider Buying and Selling

In related news, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total value of $52,012.50. Following the sale, the insider owned 1,093,313 shares of the company's stock, valued at approximately $8,199,847.50. This represents a 0.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Kush Parmar sold 27,000 shares of the company's stock in a transaction that occurred on Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total value of $202,500.00. Following the completion of the sale, the director directly owned 1,093,313 shares in the company, valued at approximately $8,199,847.50. The trade was a 2.41% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 254,000 shares of company stock worth $1,782,000. 7.59% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TRDA. Merck & Co. Inc. purchased a new position in shares of Entrada Therapeutics during the 1st quarter worth $15,728,000. Janus Henderson Group PLC increased its holdings in shares of Entrada Therapeutics by 21.6% during the 4th quarter. Janus Henderson Group PLC now owns 2,080,367 shares of the company's stock worth $36,011,000 after buying an additional 368,908 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Entrada Therapeutics by 19.7% during the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock worth $25,317,000 after buying an additional 241,052 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Entrada Therapeutics by 127.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 217,006 shares of the company's stock worth $3,752,000 after buying an additional 121,598 shares during the last quarter. Finally, Federated Hermes Inc. increased its holdings in shares of Entrada Therapeutics by 3,104.3% during the 4th quarter. Federated Hermes Inc. now owns 99,814 shares of the company's stock worth $1,726,000 after buying an additional 96,699 shares during the last quarter. Hedge funds and other institutional investors own 86.39% of the company's stock.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.